Pfizer Inc PFE

$28.72 +0.05 (0.17%)

Valuation

Market cap
163,409,648,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
PE ratio
9.31
Forward PE
9.54
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
24,950,400
Avg volume
35,986,023
Day's range
$28.39 – $28.87
Shares out
5,699,674,000
Stochastic %K
90%
Beta
0.34
Analysts
Sell
Price target
$28.92

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

RecklessRob1 Sep 29, 6:29 AM
$PFE is this going up like a rocket tomorrow?
0 replies
SellasgpsCurativeBAT11 Sep 29, 4:16 AM
$AZN $JNJ $PFE $SLS $SMMT SMMT short interest before $AZN deal: Shares Short (9/15/2026) 4 41.08M Short Ratio (9/15/2026) 4 6.44 Short % of Float (9/15/2026) 4 26.26% Short % of Shares Outstanding (9/15/2026) 4 5.15% Shares Short (prior month 8/14/2026) 4 37.43M ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Sep 29, 1:38 AM
$AZN $SMMT $JNJ $PFE $SLS Another day another massive Biotech Oncology deal: $AZN Makes $2 Billion Strategic Equity Investment in Summit Therapeutics 9/28/2026 2:30pm Investment in Preferred Shares Convertible to Common Equity, Equivalent to a Per-Share Price of Summit's Common Stock of $18.36, Representing a Premium over Today's Closing Trading Price Summit Also Enters into Clinical Trial Collaboration with AstraZeneca to Evaluate Ivonescimab in Combination with Sonesitatug Vedotin in Multiple Gastrointestinal Cancers Summit & AstraZeneca Plan to Enter into a Clinical Trial Collaboration Combining Ivonescimab with Multiple AstraZeneca ADCs and Other Cancer Medicines. $SMMT has over a Billion shares out, $AZN smart move instead of Acquiring the whole Co. $JNJ $SLS Next up. ✌️🙏❤️‍🩹
0 replies
ProTraderColin Sep 28, 11:50 PM
$PFE will we finally see 30+ again?!!
0 replies
LoneBroker Sep 28, 9:49 PM 0 replies
Noobnr1 Sep 28, 9:01 PM
$NYXH go Liam Kelly make Nyxoah great(er) and let the stockprise follow please 🚀🚀🚀 $PHAR $GILD $PFE $OMER
1 replies
SellasgpsCurativeBAT11 Sep 28, 4:38 PM
$SLS $JNJ $BMY $PFE $AZN 4 Contenders. Let’s see who walks away with # 1 Oncology prize in a Millennia. GPS CURATIVE 20+ WT1 cancers. ✌️🙏❤️‍🩹
1 replies
STOCKPICKERTRADER Sep 28, 4:36 PM
$PFE keeps bringing positive updates - good to see! Pfizer's Tilrekimig Phase 3 Program Seen as Potential Upside Driver, UBS Says MT NEWSWIRES Sep-28-2026 11:52 a.m. ET 11:52 AM EDT, 09/28/2026 (MT Newswires) -- Pfizer's (PFE) new phase 3 studies of tilrekimig in atopic dermatitis and asthma may drive upside if results are positive, UBS Securities said Friday in a report. The adult atopic-dermatitis study will be run head-to-head against Dupixent, which is developed jointly by Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) , and UBS said the potential commercial contribution is not yet reflected in consensus estimates. Topline data released in March showed competitive placebo-adjusted EASI-75 rates of about 50% at the middle and high doses, and UBS said Pfizer (PFE) is likely working to maximize efficacy at the middle-dose level.
0 replies